tiprankstipranks
Galmed Pharmaceuticals (GLMD)
NASDAQ:GLMD

Galmed Pharmaceuticals (GLMD) Income Statement

1,144 Followers

Galmed Pharmaceuticals Income Statement

Last quarter (Q4 2022), Galmed Pharmaceuticals's total revenue was $―, a decrease of ― from the same quarter last year. In Q4, Galmed Pharmaceuticals's net income was $―. See Galmed Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
---$ 0.00$ 0.00$ 2.04M
Cost of Revenue
-$ -144.48K$ -144.48K---
Gross Profit
-$ 144.48K$ 144.48K---
Operating Expense
$ 15.20M$ 17.65M$ 32.88M$ 30.21M$ 22.38M$ 12.75M
Operating Income
$ -15.20M$ -17.65M$ -32.88M$ -30.21M$ -22.38M$ -10.71M
Net Non Operating Interest Income Expense
$ -25.00K--$ 1.16M$ 1.92M$ 917.00K
Other Income Expense
-$ 215.00K$ -414.00K$ 278.00K$ -5.00K$ 17.00K
Pretax Income
$ -15.23M$ -17.87M$ -32.47M$ -28.77M$ -20.46M$ -9.78M
Tax Provision
---$ 0.00$ 0.00$ 75.00K
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -15.23M$ -17.87M$ -32.47M$ -28.77M$ -20.46M$ -9.86M
Basic EPS
$ -0.60$ 0.71$ 19.80$ -1.35$ -0.97$ -0.54
Diluted EPS
$ -0.60$ 0.71$ 19.80$ -1.35$ -0.97$ -0.54
Basic Average Shares
$ 75.37M$ 25.16M$ 1.64M$ 21.28M$ 21.11M$ 18.14M
Diluted Average Shares
$ 75.37M$ 25.14M$ 1.64M$ 21.28M$ 21.11M$ 18.14M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
---$ 430.00K$ 482.00K$ 308.00K
Total Expenses
$ 15.20M$ 17.51M$ 32.74M$ 30.21M$ 22.38M$ 12.75M
Net Income From Continuing And Discontinued Operation
$ -15.23M$ -17.87M$ -32.47M$ -28.77M$ -20.46M$ -9.86M
Normalized Income
$ -15.23M--$ -29.05M$ -20.46M$ -9.87M
Interest Expense
------
EBIT
$ -15.20M$ -17.87M$ -32.47M$ -30.21M$ -22.38M$ -10.71M
EBITDA
$ -15.18M$ -17.83M$ -32.30M$ -30.17M$ -22.34M$ -10.33M
Currency in USD

Galmed Pharmaceuticals Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis